Search Result

Results for "

GSK3A+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (1) Amyloid-β (5) Apoptosis (5) Autophagy (2) Bcl-2 Family (1) Caspase (1) CDK (5) Cholinesterase (ChE) (1) Drug Intermediate (1) DYRK (1) GSK-3 (73) HIV (1) HSV (1) Isotope-Labeled Compounds (2) Lipoxygenase (1) Microtubule/Tubulin (1) Mitophagy (1) NF-κB (4) Phosphodiesterase (PDE) (2) Pim (1) PKC (3) PROTACs (1) Reactive Oxygen Species (1) Reference Standards (1) ROS Kinase (1) Tau Protein (6) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (27) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (12) Metabolic Disease (25) Neurological Disease (45)

By Targets:

AAK1 (1)

Amyloid-β (5)

Apoptosis (5)

Autophagy (2)

Bcl-2 Family (1)

Caspase (1)

CDK (5)

Cholinesterase (ChE) (1)

Drug Intermediate (1)

DYRK (1)

GSK-3 (73)

HIV (1)

HSV (1)

Isotope-Labeled Compounds (2)

Lipoxygenase (1)

Microtubule/Tubulin (1)

Mitophagy (1)

NF-κB (4)

Phosphodiesterase (PDE) (2)

Pim (1)

PKC (3)

PROTACs (1)

Reactive Oxygen Species (1)

Reference Standards (1)

ROS Kinase (1)

Tau Protein (6)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (27)

Cardiovascular Disease (1)

Infection (3)

Inflammation/Immunology (12)

Metabolic Disease (25)

Neurological Disease (45)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-126144A

*(E/Z)-GSK-3β inhibitor* 1**	GSK-3	Metabolic Disease
(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC₅₀ of 4.9 nM .

HY-112392

GSK-3 Inhibitor XIII	GSK-3	Cancer
GSK-3 Inhibitor XIII is a potent and ATP-competitive *GSK-3* inhibitor with a K_i of 24 nM .

HY-130795

*GSK-3β inhibitor* 2** 1 Publications Verification	GSK-3	Neurological Disease
GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active *GSK-3β* inhibitor with an IC₅₀ of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease .

HY-112388

*GSK-3b Inhibitor* XI**	GSK-3	Neurological Disease Metabolic Disease
GSK-3b Inhibitor XI (Compound 33) is a potent and selective *GSK3β* inhibitor, with a K_i value of 25 nM. GSK-3b Inhibitor XI increases glycogen synthase (GS) activity. GSK-3b Inhibitor XI can be used for research on type 2 diabetes and Alzheimer’s disease .

HY-164907

*GSK-3β inhibitor* 22**	GSK-3	Neurological Disease
GSK-3β inhibitor 22 (compound 20o) is a *GSK-3β* inhibitor with an IC₅₀ of 3.1 nM. GSK-3β inhibitor 22 has the potential of the study of Alzheimer's disease .

HY-147134

*GSK-3β inhibitor* 10**	GSK-3	Neurological Disease
GSK-3β inhibitor 10 (compound 14a) is a highly potent *GSK-3β* inhibitor with an IC₅₀ value of 80.5 nM. GSK-3β inhibitor 10 can be used for researching Alzheimer’s disease .

HY-126201

GSK-3 inhibitor 7	GSK-3	Neurological Disease
GSK-3 inhibitor 7 (compound 22) is a glycogen synthase kinase-3 (GSK-3) inhibitor. GSK-3 inhibitor 7 can be used in nervous system research .

HY-169024

*GSK-3β inhibitor* 19**	GSK-3	Neurological Disease Inflammation/Immunology
GSK-3β inhibitor 19 (compound 36) is a *GSK-3β* inhibitor, with IC₅₀ of 70 nM. GSK-3β inhibitor 19 can be used in anti-inflammatory and Alzheimer's disease related research .

HY-169602

*GSK-3β inhibitor* 26**	GSK-3	Neurological Disease Inflammation/Immunology Cancer
GSK-3β inhibitor 26 (Compound D14) is a *GSK-3β* inhibitor with an IC₅₀ of 18.23 μM. GSK-3β inhibitor 26 can be used in the research of cancer, inflammation and neurodegenerative diseases .

HY-143260

*GSK-3β inhibitor* 6**	GSK-3	Metabolic Disease Inflammation/Immunology Cancer
GSK-3β inhibitor 6 is a potent *GSK-3β* inhibitor with an IC₅₀ value of 24.4 μM. GSK-3β inhibitor 6 shows high hepatocyte glucose uptake (38%). GSK-3β inhibitor 6 can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .

HY-149542

*GSK-3β inhibitor* 15**	Tau Protein Apoptosis GSK-3	Neurological Disease
GSK-3β inhibitor 15 (Compound 54) is a *GSK-3β* inhibitor (IC₅₀: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ_1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ_1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD) .

HY-168857

*GSK-3β inhibitor* 24**	GSK-3 Tau Protein β-catenin	Neurological Disease
GSK-3β inhibitor 24 (Compound 41) is a potent *GSK-3β* inhibitor with an IC₅₀ of 0.22 nM. GSK-3β inhibitor 24 increases GSK-3β phosphorylation at Ser9 site dose-dependently. GSK-3β inhibitor 24 inhibits the hyperphosphorylation of tau protein by decreasing the p-tau-Ser396 abundance. GSK-3β inhibitor 24 up-regulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2). GSK-3β inhibitor 24 demonstrates remarkable anti-Alzheimer's disease (AD) effects .

HY-14679

*GSK3β inhibitor* II**	GSK-3	Neurological Disease
GSK3β inhibitor II is an inhibitor of *GSK3β. GSK3β inhibitor* II can be used for research of Alzheimer’s disease (AD) .

HY-148132

*GSK-3β inhibitor* 11**	GSK-3	Neurological Disease
GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC₅₀=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research .

HY-153760

*GSK-3β inhibitor* 14**	GSK-3	Neurological Disease Metabolic Disease
GSK-3β inhibitor 14 (Compound 6i), benzothiazepinone derivative, is a weak *GSK-3β* inhibitor (IC₅₀ >100 μM) .

HY-168079

*GSK-3β inhibitor* 21**	GSK-3 Tau Protein	Neurological Disease Inflammation/Immunology
GSK-3β inhibitor 21 (compound 44) is an ATP-competitive *GSK-3β* inhibitor (IC₅₀=6.06 μM) with anti-amyloid aggregation and tau phosphorylation inhibitory activities. GSK-3β inhibitor 21 can be used in the study of Alzheimer's disease .

HY-161458

*GSK-3β inhibitor* 16**	GSK-3 Tau Protein	Neurological Disease
GSK-3β inhibitor 16 (compound 7c) is a *GSK-3β* inhibitor with the IC₅₀ of 4.68 nM. GSK-3β inhibitor 16 decreases Tau hyperphosphorylated aggregate and alleviates cognitive impairments in the Scopolamin (HY-N0296)-induced model in mice .

HY-163748

*GSK-3β inhibitor* 17**	GSK-3	Inflammation/Immunology
GSK-3β inhibitor 17 (compound 5 n) is a potent *GSK-3β* inhibitor. GSK-3β inhibitor 17 decreases cisplatin (HY-17394) induced p-p65, KIM-1 protein and mRNA expression. GSK-3β inhibitor 17 decreases cisplatin induced TNF-α, IL-1β, IL-6 and MCP-1 mRNA expression. GSK-3β inhibitor 17 shows anti-inflammation effect and has the potential for the research of acute kidney injury .

HY-143261

*GSK-3β inhibitor* 7**	GSK-3	Metabolic Disease Inflammation/Immunology Cancer
GSK-3β inhibitor 7 is a *GSK-3β* inhibitor with an IC₅₀ value of 5.25 μM. GSK-3β inhibitor 7 is inserted into the ATP-binding binding pocket of GSK-3β and forms hydrogen-bond. GSK-3β inhibitor 7 shows high hepatocyte glucose uptake (83.5%), and can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .

HY-149054

*GSK-3β inhibitor* 13**	GSK-3 Tau Protein AAK1 Pim PKC	Neurological Disease
GSK-3β inhibitor 13 (compound 47) is an orally active and potent *GSK-3β* inhibitor with blood-brain permeability. GSK-3β inhibitor 13 inhibits *GSK-3β* and *GSK-3α* with IC₅₀s of 0.73 nM and 0.35 nM, respectively. GSK-3β inhibitor 13 significantly decreases the phosphorylation of tau (IC₅₀=58 nM), which leads the formation of the neurofibrillary tangles associated with Alzheimer's disease .

HY-162722

GSK-3 inhibitor 6	GSK-3	Others
GSK-3 inhibitor 6 (2) is a CNS penetrated *GSK-3* inhibitor, with IC₅₀ values of 29 nM and 24 nM for GSK-3α and GSK-3β, respectively .

HY-148133

*GSK-3β inhibitor* 12**	GSK-3	Neurological Disease
GSK-3β inhibitor 12 (compound 15) is an inhibitor of *GSK-3β. GSK-3β inhibitor* 12 inhibits 49.11% and 37.11% activity of 25 μM and 50 μM GSK-3β, respectively. GSK-3β inhibitor 12 can be used for the research of neurodegenerative diseases .

HY-13973A

GSK-3 inhibitor 1 1 Publications Verification	GSK-3	Metabolic Disease
GSK-3 inhibitor 1 (compound core 3) is a *GSK-3* inhibitor that induces stem/progenitor cell self-renewal (e.g. induces stem/progenitor cell proliferation while maintaining the ability to differentiate into tissue cells in the progeny) .

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of *GSK-3, CDK2, and CDK5, with IC₅₀* values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-126144

*GSK-3β inhibitor* 1** 3 Publications Verification	GSK-3	Metabolic Disease Cancer
GSK-3β inhibitor 1 (compound 3a) inhibits *GSK-3β* with an IC₅₀ of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats .

HY-154851

GSK-3 inhibitor 3	GSK-3 CDK Tau Protein	Neurological Disease
GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of *GSK-3, with IC₅₀s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3* inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimer’s disease model, with IC₅₀ of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research .

HY-120902

*GSK-3β inhibitor* 8**	Wnt GSK-3	Inflammation/Immunology
GSK-3β inhibitor 8, a thiophenacil derivative, is an effective and selective inhibitor of *GSK-3β* (IC₅₀=64 nM). GSK-3β inhibitor 8 negatively regulated Wnt signaling pathway and stimulated β cell proliferation .

HY-141480

*GSK-3β inhibitor* 3**	GSK-3 Apoptosis	Cancer
GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC₅₀ of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia .

HY-170491

*GSK-3β inhibitor* 23**	GSK-3	Infection Neurological Disease
GSK-3β inhibitor 23 (Compound 11726169) is the inhibitor for glycogen synthase kinase-3, that inhibits *GSK-3β* and *GSK-3α* with IC₅₀ of 12.1 nM and 18.8 nM. GSK-3β inhibitor 23 exhibits antiviral activity against HIV 1. GSK-3β inhibitor 23 exhibits good metabolic stablility in mouse/human liver microsomes and plasma, but poor Caco-2 permeability (which predicts low oral bioavailability) .

HY-117194

18BIOder	HIV GSK-3	Infection
18BIOder is a neuroprotective *GSK-3*β inhibitor, highly selectively inhibiting HIV-1 .

HY-30236

5-Bromoindole	Drug Intermediate	Cancer
5-Bromoindole is a chemical intermediate that can be used for the synthesis of GSK-3 inhibitors and anti-cancer agents .

HY-10512

AR-A014418 15+ Cited Publications AR 0133418; GSK 3β inhibitor VIII; AR 014418	GSK-3	Metabolic Disease Cancer
AR-A014418 is a potent, selective and ATP-competitive *GSK3β* inhibitor (IC₅₀=104 nM; K_i=38 nM) .

HY-162638

*GSK-3β inhibitor* 18**	GSK-3	Neurological Disease
GSK-3β inhibitor 18 (compound 2) is a potent inhibitor of *GSK-3β, with the IC₅₀* of 0.0021 μM .

HY-162913

*GSK-3β inhibitor* 20**	GSK-3	Neurological Disease
GSK-3β inhibitor 20 (compound 3A) is an potent inhibitor of GSK-3β with an IC₅₀ value of 74.4 nM .

HY-107530

3F8	GSK-3	Cardiovascular Disease Metabolic Disease Cancer
3F8 is a potent and selective *GSK-3β* inhibitor that could be useful as new reagent and potential therapeutic candidate for GSK3 related diseases .

HY-12074

Cazpaullone	GSK-3	Metabolic Disease
Cazpaullone is a glycogen synthase kinase-3 (GSK-3) inhibitor. Cazpaullone can activate pancreatic beta cell protection and replication. Cazpaullone can be used for the research of diabetes .

HY-Q48328

GSK3-IN-1	GSK-3	Metabolic Disease
GSK3-IN-1 (compound 11) is a *GSK-3* inhibitor with an IC₅₀ value of 12 μM. GSK3-IN-1 can be used in the research of diabetes .

HY-12012

SB 216763 30+ Cited Publications	GSK-3 Autophagy	Neurological Disease Cancer
SB 216763 is potent, selective and ATP-competitive *GSK-3* inhibitor with IC₅₀s of 34.3 nM for both GSK-3α and GSK-3β.

HY-100207

CP21R7 5+ Cited Publications CP21	GSK-3	Cancer
CP21R7 is potent *GSK-3β* inhibitor, with an IC₅₀ of 1.8 nM; CP21R7 also shows inhibitory activitiy against PKCα, with an IC₅₀ of 1900 nM.

HY-15356

BIO-acetoxime 1 Publications Verification BIA	GSK-3 Apoptosis HSV	Infection Neurological Disease Inflammation/Immunology
BIO-acetoxime (BIA) is a potent and selective *GSK-3* inhibitor, with IC₅₀s of both 10 nM for GSK-3α/β. BIO-acetoxime has anticonvulsant and anti-infection activity.

HY-169606

*GSK-3β inhibitor* 25**	GSK-3	Neurological Disease Metabolic Disease
GSK-3β inhibitor 25 (Compound 6h) exhibits a weak inhibitory activity against *GSK-3β* wih an IC₅₀>100 μM .

HY-15761

AZD2858 5+ Cited Publications	GSK-3	Neurological Disease
AZD2858 is a potent, orally active *GSK-3* inhibitor, with IC₅₀s of 0.9 and 5 nM for *GSK-3α* and *GSK-3β*, respectively, used in the research of fracture healing.

HY-169632

GSK3β-IN-1	GSK-3	Neurological Disease
GSK3β-IN-1 (compound 1) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC₅₀=65 nM), which can be used in the study of Alzheimer's disease .

HY-13867A

Bisindolylmaleimide I hydrochloride Maximum Cited Publications 36 Publications Verification GF109203X hydrochloride; Go 6850 hydrochloride	PKC GSK-3	Metabolic Disease Cancer
Bisindolylmaleimide I (GF109203X) hydrochloride is a cell-permeable and reversible PKC inhibitor (IC₅₀ of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I hydrochloride is also a *GSK-3* inhibitor ^[3].

HY-14872

Tideglusib 5 Publications Verification NP031112	GSK-3	Neurological Disease
Tideglusib (NP031112) is an irreversible *GSK-3* inhibitor with IC₅₀s of 5 nM and 60 nM for GSK-3β ^WT (1 h preincubation) and GSK-3β ^C199A (1 h preincubation), respectively.

HY-111055

BIP-135	GSK-3	Neurological Disease
BIP-135 is a potent and selective ATP-competitive *GSK-3* inhibitor, with IC₅₀s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect .

HY-13867

Bisindolylmaleimide I Maximum Cited Publications 36 Publications Verification GF109203X; Go 6850	PKC GSK-3	Metabolic Disease Cancer
Bisindolylmaleimide I (GF109203X) is a cell-permeable and reversible PKC inhibitor (IC₅₀ of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I is also a *GSK-3* inhibitor ^[3].

HY-124607B

BRD3731 1 Publications Verification	GSK-3	Neurological Disease Metabolic Disease
BRD3731 is a selective *GSK3β* inhibitor, with IC₅₀s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders .

HY-10512S

AR-A014418-d3 AR 0133418-d₃; GSK 3β inhibitor VIII-d₃; AR 014418-d₃	Isotope-Labeled Compounds GSK-3	Metabolic Disease Cancer
AR-A014418-d₃ is the deuterium labeled AR-A014418. AR-A014418 is a potent, selective, and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM)[1].

HY-10512R

AR-A014418 (Standard) AR 0133418 (Standard); GSK 3β inhibitor VIII (Standard); AR 014418 (Standard)	GSK-3	Metabolic Disease Cancer
AR-A014418 (Standard) is the analytical standard of AR-A014418. This product is intended for research and analytical applications. AR-A014418 is a potent, selective and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM) .

Cat. No.	Product Name	Target	Research Area

HY-P1173

L803-mts Myristoylated L 803; GSK-3β Inhibitor XIII	GSK-3 Amyloid-β	Neurological Disease
L803-mts (Myristoylated L 803) is a selective and substrate-competitive *GSK-3* peptide inhibitor (IC₅₀: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test .

Cat. No.	Product Name	Chemical Structure

HY-10512S

AR-A014418-d3
AR-A014418-d₃ is the deuterium labeled AR-A014418. AR-A014418 is a potent, selective, and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM)[1].

HY-B1619S

Cromolyn-d5

Cromolyn-d₅ (Cromoglycate-d₅) is the deuterium labeled Cromolyn (HY-B1619). Cromolyn (Cromoglycate) is an orally active GSK-3β inhibitor with an IC₅₀ of 2.0 μM. Cromolyn is also a mast cell stabilizer that can inhibit the release of mediators from mast cells, regulate reflex bronchoconstriction, and reduce non-specific bronchial hyperreactivity, and Cromolyn can be used in the research of bronchial asthma. In addition, Cromolyn has multiple activities such as anti-inflammatory, anti-allergic, anti-histamine, anti-cancer, and neuroprotective effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: